Cargando…
Profile of suvorexant in the management of insomnia
Suvorexant, approved in late 2014 in the United States and Japan for the treatment of insomnia characterized by difficulty achieving and/or maintaining sleep, is a dual orexin receptor antagonist and the first drug in its class to reach the market. Its development followed from the 1998 discovery of...
Autor principal: | Sutton, Eliza L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651361/ https://www.ncbi.nlm.nih.gov/pubmed/26648692 http://dx.doi.org/10.2147/DDDT.S73224 |
Ejemplares similares
-
Suvorexant: a promising, novel treatment for insomnia
por: Lee-Iannotti, Joyce K, et al.
Publicado: (2016) -
Suvorexant for insomnia in older adults: a perspective review
por: Tampi, Rajesh R, et al.
Publicado: (2018) -
Suvorexant: The first orexin receptor antagonist to treat insomnia
por: Dubey, Ashok K., et al.
Publicado: (2015) -
Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant
por: Norman, Jessica L, et al.
Publicado: (2016) -
Assessment of Switching to Suvorexant versus the Use of Add-on Suvorexant in Combination with Benzodiazepine Receptor Agonists in Insomnia Patients: A Retrospective Study
por: Hatano, Masakazu, et al.
Publicado: (2018)